Bevacizumab for glioblastoma

Area of Science:

• Neuro-oncology
• Medical oncology
• Clinical pharmacology

Background:

• Glioblastoma is aggressive, often presenting with poor prognostic factors like advanced age and neurological deficits.
• Current treatments for glioblastoma have limited efficacy, highlighting the need for improved therapeutic strategies.
• Bevacizumab (BV) is an anti-angiogenic agent investigated for its potential benefits in malignant gliomas.

Purpose of the Study:

• To review the efficacy and safety of bevacizumab (BV) in treating glioblastoma.
• To evaluate the impact of BV on tumor regression, cerebral edema, and neurological status.
• To discuss the challenges and considerations for BV administration in glioblastoma patients.

Main Methods:

• Literature review of studies evaluating bevacizumab in glioblastoma.
• Analysis of data on tumor response, progression-free survival, overall survival, and performance status.
• Assessment of adverse events associated with bevacizumab treatment.

Main Results:

• Bevacizumab (BV) promotes tumor regression and improves cerebral edema in glioblastoma.
• Addition of BV to standard chemoradiotherapy with temozolomide prolonged progression-free survival and improved performance status.
• Bevacizumab did not extend overall survival in newly diagnosed glioblastoma patients.

Conclusions:

• Bevacizumab (BV) offers benefits in managing symptoms and maintaining performance status in glioblastoma patients.
• BV should be considered as an initial treatment option, especially for patients with poor performance status at diagnosis.
• Careful explanation of BV's advantages, disadvantages, and potential adverse events is crucial for patient management.